Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Double Blinded, Randomized, Placebo- Controlled Study to Examine the Safety and Immunogenicity of a Seasonal Trivalent Split Inactivated Influenza Vaccine Produced by Institute Torlak in 18-65 Year Old Volunteers in Serbia

NCT02935192 is registered in ClinicalTrials.gov with Institute of Virology, Vaccines and Sera, Torlak as lead sponsor.

NCT NCT02935192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02935192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Double Blinded, Randomized, Placebo- Controlled Study to Examine the Safety and Immunogenicity of a Seasonal Trivalent Split Inactivated Influenza Vaccine Produced by Institute Torlak in 18-65 Year Old Volunteers in Serbia
Lead sponsor
Institute of Virology, Vaccines and Sera, Torlak
Phase
Phase 3
Overall status
Completed
Start date
November 28, 2016
Completion date
March 25, 2017
Enrollment
480 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

influenza